FDA Starts Its Second Safety Investigation Into Novartis/Orion's Parkinson's Drug Stalevo
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA meta-analysis reveals a cardiovascular safety risk with Orion and Novartis' Stalevo, on top of an ongoing review of a prostate cancer imbalance, but uncertainty about the data raises the question of whether FDA will want a prospective heart safety study.
You may also be interested in...
Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change
The Mini-Sentinel medical products safety surveillance project will assess the health impact of FDA-mandated label warnings for use of long-acting beta agonists in asthma, Harvard Pilgrim Health Care Institute’s Richard Platt noted during a Sept. 15 webinar on Mini-Sentinel sponsored by the Brookings Institution.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.